University of Illinois at Chicago, Ocugen deal

The university granted Ocugen exclusive, worldwide rights to develop and commercialize OCU300. The repurposed undisclosed drug showed beneficial effect in about 90% of patients in a post hoc analysis of an exploratory observational study in ocular graft-versus-host disease (GvHD). ...